Shanghai TTM-Bio Technology Co., Ltd

Bengbu, Anhui

OncologyPhase I

Compare Sign in to watch

What changed

NIH R01 · $0.6M · Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.

6w agoNew grantJun 5, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $582k · non-dilutive
Jun 2, 2026
UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · NCI · award ends May 31, 2031 · Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.
NIH RePORTER · NIH RePORTER 11343411 (opens the source filing in a new tab)
Grant
R01 · $561k · non-dilutive
Jun 2, 2026
UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · NCI · award ends May 31, 2031 · Role of p73-mediated DR5 induction in therapeutic response to CDK inhibition.
NIH RePORTER · NIH RePORTER 11343650 (opens the source filing in a new tab)
Grant
R21 · $197k · non-dilutive
May 5, 2026
STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ZHANG, LIN · NINDS · award ends Apr 30, 2028 · Conformable Cranial Ultrasound Patch for Monitoring Neonates with Germinal Matrix Hemorrhage
NIH RePORTER · NIH RePORTER 11356805 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 6, 2025
Osteoporotic Fracture · ENROLLING_BY_INVITATION · sponsor: Shanghai TTM-Bio Technology Co., Ltd · Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
ClinicalTrials.gov · NCT07178327 (opens the source filing in a new tab)
Grant
R25 · $300k · non-dilutive
Aug 1, 2025
UNIVERSITY OF MINNESOTA · PI ZHANG, LIN · NIDA · award ends Jul 31, 2028 · Reproducible Research in Brain Imaging Genetics
NIH RePORTER · NIH RePORTER 11249058 (opens the source filing in a new tab)
Grant
R01 · $553k · non-dilutive
Jan 1, 2025
UNIVERSITY OF PENNSYLVANIA · PI ZHANG, LIN · NCI · award ends Dec 31, 2029 · KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors
NIH RePORTER · NIH RePORTER 11252542 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator ZHANG, LIN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.26no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.6M · Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.
6w agoNew grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Role of p73-mediated DR5 induction in therapeutic response to CDK inhibition.
6w agoNew grantSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Conformable Cranial Ultrasound Patch for Monitoring Neonates with Germinal Matrix Hemorrhage
2mo agoNew grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors
7mo agoGrant renewalSource (opens the source filing in a new tab)
Phase I trial registered: Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
10mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R25 · $0.3M · Reproducible Research in Brain Imaging Genetics
Jul 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $582k · non-dilutive

R01 · $561k · non-dilutive

R21 · $197k · non-dilutive

PHASE1 registered

R25 · $300k · non-dilutive

R01 · $553k · non-dilutive